Insider Trading November 10, 2026 11:46 PM

Xometry Director Fabio Rosati Offloads $216,938 in Shares Near 52-Week High

The sale, executed under a pre-arranged 10b5-1 plan, comes as Xometry stock has more than doubled year-to-date and follows a strong third-quarter earnings report.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
XMTR

Fabio Rosati, a director at Xometry, Inc. (NASDAQ:XMTR), sold 1,800 shares of Class A common stock on November 9, 2026, for a total value of $216,938. The shares were sold at prices between $119.334 and $122.3819, close to the stock's 52-week high of $123.39. The transaction was executed automatically under a Rule 10b5-1 trading plan adopted at least 90 days prior. Following the sale, Rosati indirectly beneficially owns 89,867 shares through The Fabio Rosati 2022 Family Trust. The stock has delivered exceptional returns, up over 100% year-to-date and 82% over the past year. Xometry recently reported impressive third-quarter results, surpassing expectations with adjusted earnings of $0.28 per share and revenue of $252.4 million, a 40% increase year-over-year, including the company's first quarter of GAAP net income. Several analysts have raised their price targets following the strong performance.

Xometry Director Fabio Rosati Offloads $216,938 in Shares Near 52-Week High
XMTR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Fabio Rosati sold 1,800 Xometry shares for $216,938 under a pre-arranged 10b5-1 plan, near the stock's 52-week high.
  • Xometry's third-quarter results showed 40% revenue growth to $252.4 million, with adjusted EPS of $0.28 and its first GAAP net income, prompting analyst price target hikes.
  • The industrial and manufacturing sector, particularly digital manufacturing platforms, may be impacted by Xometry's performance and insider activity as a signal of sector health.

Xometry, Inc. (NASDAQ:XMTR) director Fabio Rosati sold 1,800 shares of the company's Class A common stock on November 9, 2026, according to a regulatory filing. The transaction was valued at $216,938, with share prices ranging from $119.334 to $122.3819. The sale occurred near the stock's 52-week high of $123.39, a level that underscores the strong rally in Xometry shares.

The stock has been a standout performer, climbing more than 100% year-to-date and 82% over the past year. Such gains often prompt insiders to lock in profits, and Rosati's sale fits that pattern. However, the transaction was not a discretionary move: it was executed automatically pursuant to a Rule 10b5-1 trading plan, which Rosati had adopted at least 90 days before the trade date. Such plans are designed to remove the potential for insider trading by scheduling sales in advance, and they provide a defense against claims that material nonpublic information influenced the timing.

Following the sale, Rosati indirectly beneficially owns 89,867 shares of Xometry Class A common stock through The Fabio Rosati 2022 Family Trust. The disclosure of this remaining stake offers context on his continued exposure to the company's performance.

The sale comes on the heels of a robust third-quarter earnings report that has bolstered investor confidence. Xometry reported adjusted earnings of $0.28 per share and revenue of $252.4 million, surpassing analyst expectations. Revenue grew 40% compared to the prior-year period, and the quarter marked the company's first period of GAAP net income. Marketplace revenue, a key segment, expanded 43% year-over-year to $238 million. Adjusted EBITDA reached $21.4 million, exceeding consensus estimates by approximately 28%. The company also achieved record metrics in total revenue, gross profit, and the highest-ever Marketplace gross margin.

Analysts have responded positively. Cantor Fitzgerald, Wedbush, and Citizens all raised their price targets for Xometry following the quarterly performance. Cantor Fitzgerald increased its target to $114, while Wedbush and Citizens raised theirs to $140 and $135, respectively. These target revisions reflect a constructive view on Xometry's growth trajectory.

In addition, Xometry has raised its guidance for the fourth quarter of 2026 by approximately $7 million, signaling management's confidence in continued momentum. The combination of strong quarterly results, analyst upgrades, and raised guidance paints a favorable picture for the company's near-term prospects.

Still, the stock's valuation has drawn some attention. According to InvestingPro analysis, Xometry shares currently appear overvalued relative to their Fair Value. This assessment suggests that while the company's operational performance has been strong, the market price may have run ahead of underlying fundamentals. Investors seeking deeper insights can access Xometry's comprehensive Pro Research Report, one of 1,400+ available for US equities, along with 15 additional ProTips.

For those tracking insider activity, Rosati's sale is a notable event given its proximity to the 52-week high and the stock's impressive run. However, the pre-arranged nature of the transaction and the fact that he retains a significant indirect stake may temper concerns about his confidence in the company. Insider sales can be interpreted in various ways, and the context of a 10b5-1 plan is an important factor in that analysis.

Xometry operates in the manufacturing and industrial sector, providing a marketplace that connects buyers with custom parts manufacturers. The company's performance is often seen as a barometer for broader trends in industrial demand and digital manufacturing. The strong revenue growth and improved profitability suggest that Xometry is capitalizing on these trends, though the valuation question remains a point of debate among investors.

As the fourth quarter progresses, market participants will watch whether Xometry can sustain its growth and whether insider activity continues. For now, the sale by Rosati adds to the narrative of a stock that has rewarded shareholders handsomely but may be due for a pause.

Risks

  • InvestingPro analysis indicates Xometry stock may be overvalued relative to Fair Value, posing a risk of price correction that could affect the technology and industrial sectors.
  • Insider sales, even under pre-arranged plans, can be perceived negatively by the market and may pressure the stock, particularly in the high-growth technology segment.
  • The company's ability to sustain its growth trajectory and meet raised guidance is uncertain, with potential implications for the broader manufacturing economy.

More from Insider Trading

HCA Healthcare's Chief Nurse Executive Offloads $1.77 Million in Shares Nov 11, 2026 Drilling Tools International CEO Robert Prejean Buys 100,000 Shares for $164,300 Nov 11, 2026 Kontoor Brands Executive Sells Shares Worth $511,803 Nov 11, 2026 Aware CEO Ajay Amlani Purchases 4,000 Shares as Stock Trades Below $1 Nov 11, 2026 Floor & Decor EVP Ersan Sayman Offloads $1.11M in Stock Nov 11, 2026